Literature DB >> 11745467

Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes.

I Zehbe1, R Tachezy, J Mytilineos, G Voglino, I Mikyskova, H Delius, A Marongiu, L Gissmann, E Wilander, M Tommasino.   

Abstract

Infection with high-risk human papillomavirus (HPV) is necessary for the development of a cervical lesion, but only a fraction of precursor lesions progress to cancer. Additional factors, other than HPV type per se, are likely to increase the probability for progression. Intratype genome variations have been reported to be associated with viral persistence and the development of a major cervical disease. We have recently shown that the prevalence of specific HPV16-E6 variants in invasive cervical cancer (ICC) varies between Italian and Swedish women. To extend our initial study we have analyzed E6 variants in cervical lesions from Czech women, ranging from low-grade cervical intraepithelial neoplasia (LCIN) to ICC and scaled up the sample size of our initial study of Swedish and Italian women. In addition, we have correlated the cases of cancers with human leukocyte antigen (HLA) class II haplotypes. In line with our earlier observation, the distribution of specific HPV16-E6 genotypes in CIN and ICC varied in the 3 cohorts. For instance, the HPV16-E6 L83V variant, which has been found to be positively associated with ICC in Swedish women (p = 0.002), was more prevalent in LCIN than in ICC in Italian and Czech women (p = 0.01 and = 0.03, respectively). These data indicate that host genetic factors, such as HLA polymorphism, may determine the potential oncogenicity of the HPV16-E6 L83V variant. Indeed, the DR04-DQ03 haplotype, which is approximately 3-fold more abundant in the normal Swedish population than in those in Italy and the Czech Republic, was found to be positively associated with HPV16-E6 L83V in the 3 cohorts investigated (p = 0.01). This observation may explain why L83V is a risk factor more in Sweden than in the other 2 countries. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745467     DOI: 10.1002/ijc.1520

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses.

Authors:  Zigui Chen; Masanori Terai; Leiping Fu; Rolando Herrero; Rob DeSalle; Robert D Burk
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

2.  Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis.

Authors:  Ingeborg Zehbe; Christina Richard; Correne A DeCarlo; Anny Shai; Paul F Lambert; Hava Lichtig; Massimo Tommasino; Levana Sherman
Journal:  Virology       Date:  2008-11-04       Impact factor: 3.616

3.  Entire genome characterization of human papillomavirus type 16 from infected Thai women with different cytological findings.

Authors:  Woradee Lurchachaiwong; Pairoj Junyangdikul; Sunchai Payungporn; Jira Chansaenroj; Pichet Sampathanukul; Damrong Tresukosol; Wichai Termrungruanglert; Apiradee Theamboonlers; Yong Poovorawan
Journal:  Virus Genes       Date:  2009-05-03       Impact factor: 2.332

4.  Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer.

Authors:  Alyce A Chen; Daniëlle A M Heideman; Debby Boon; Zigui Chen; Robert D Burk; Hugo De Vuyst; Tarik Gheit; Peter J F Snijders; Massimo Tommasino; Silvia Franceschi; Gary M Clifford
Journal:  Virology       Date:  2013-11-12       Impact factor: 3.616

5.  HPV16 genetic variation and the development of cervical cancer worldwide.

Authors:  I Cornet; T Gheit; M R Iannacone; J Vignat; B S Sylla; A Del Mistro; S Franceschi; M Tommasino; G M Clifford
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

6.  Human papillomavirus (HPV) 16 E6 variants in tonsillar cancer in comparison to those in cervical cancer in Stockholm, Sweden.

Authors:  Juan Du; Cecilia Nordfors; Anders Näsman; Michal Sobkowiak; Mircea Romanitan; Tina Dalianis; Torbjörn Ramqvist
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

7.  Rare human papillomavirus 16 E6 variants reveal significant oncogenic potential.

Authors:  Ingeborg Zehbe; Hava Lichtig; Ashley Westerback; Paul F Lambert; Massimo Tommasino; Levana Sherman
Journal:  Mol Cancer       Date:  2011-06-24       Impact factor: 27.401

8.  Genetic epidemiology of glioblastoma multiforme: confirmatory and new findings from analyses of human leukocyte antigen alleles and motifs.

Authors:  Wei Song; Avima M Ruder; Liangyuan Hu; Yufeng Li; Rong Ni; Wenshuo Shao; Richard A Kaslow; MaryAnn Butler; Jianming Tang
Journal:  PLoS One       Date:  2009-09-23       Impact factor: 3.240

9.  Characterization and whole genome analysis of human papillomavirus type 16 e1-1374^63nt variants.

Authors:  Ivan Sabol; Mihaela Matovina; Ali Si-Mohamed; Magdalena Grce
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

10.  Human papillomavirus type 16 E6 variants in France and risk of viral persistence.

Authors:  Iris Cornet; Tarik Gheit; Gary M Clifford; Jean-Damien Combes; Véronique Dalstein; Silvia Franceschi; Massimo Tommasino; Christine Clavel
Journal:  Infect Agent Cancer       Date:  2013-01-23       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.